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Abstract 
Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit 
behind diverse complications. Adiponectin is known to have anti‑atherogenic and cardio‑protective effects. Mean‑
while, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has 
not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic 
syndrome in patients with chronic kidney disease.
Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that 
enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were 
collected from 1332 patients with chronic kidney disease.
Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin 
level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log 
adiponectin was positively associated with high‑density lipoprotein cholesterol levels (β = 0.006), whereas it was 
negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C‑reactive pro‑
tein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis 
indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 
1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898–0.970, P < 0.001) after adjustment for multiple 
confounding factors.
Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in 
patients with chronic kidney disease.
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Background
Metabolic syndrome is defined as the aggregation of 
non-traditional risk factors, including central obesity, 
hypertension, hyperglycemia, hypertriglyceridemia, and 
decreased high-density lipoprotein cholesterol (HDL-C) 
[1]. The clinical significance of metabolic syndrome is its 
association with endocrinologic derangement, cardiovas-
cular events [2], and renal impairment [3] in the general 
population. In addition, unfavorable clinical relationships 
were also reported in patients with chronic kidney dis-
ease on maintenance dialysis [4].
Adiponectin, which is released from adipocytes [5], 
is known to have anti-atherogenic and cardio-protec-
tive effects. It is chiefly related to insulin resistance and 
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systemic inflammation, which are important factors 
for non-traditional risks of adverse outcome in chronic 
kidney disease [6]. Hypoadiponectinemia is related to 
metabolic syndrome [7] and increased intima-media 
thickness, which is a well-known early indicator of ath-
erosclerosis in the general population [8] and in patients 
with chronic kidney disease [9]. However, the relation-
ship between adiponectin level and metabolic syndrome 
in patients with chronic kidney disease has not been 
definitely clarified [10]. Decreased estimated glomerular 
filtration rate (eGFR), which is a well-known risk fac-
tor of metabolic syndrome, is significantly and indepen-
dently related to hyperadiponectinemia in patients with 
chronic kidney disease [11]. In addition, several medica-
tions affecting adiponectin level and metabolic derange-
ments such as statins or fibrates were not considered in 
most previous research studies. Regarding the important 
impact on clinical outcomes of metabolic syndrome in 
patients with chronic kidney disease, clarification of the 
relationship between metabolic syndrome and adiponec-
tin level is mandatory.
Therefore, the aim of this study is to clarify the deter-
minant factors of adiponectin level, and elucidate the 
relationship between adiponectin level and metabolic 
syndrome in patients with chronic kidney disease.
Methods
Subjects
The study has a cross-sectional design, using the data-
base system of the KoreaN Cohort Study for Outcome 
in Patients with Chronic Kidney Disease (KNOW-
CKD), a nationwide multicenter prospective cohort 
including chronic kidney disease stage 1–5 pre-dialysis 
patients from February 2011 to July 2014. KNOW-CKD 
was implemented to investigate the pathophysiologic 
mechanisms of renal or cardiovascular outcomes in 
Korean chronic kidney disease populations. The detailed 
design and methods of the KNOW-CKD were previ-
ously published [12]. Among 1528 patients, 73 patients 
were excluded due to unavailable eGFR or adiponectin 
data, and 133 patients were also excluded due to miss-
ing data on blood pressure, waist measurement, triglyc-
erides, HDL-C, or glucose. A total of 1322 patients were 
included in the final analysis.
Data collection
All data analyzed in this study were collected at the 
time of enrollment. The demographic data were col-
lected by experienced doctors and nurses from the study 
subjects. Body mass index was calculated as weight in 
kilograms divided by the square of height in meters 
[13], and the measurements of baseline blood pres-
sure were performed in the clinic using an electronic 
sphygmomanometer. The use of medication at the time 
of enrollment was determined by a specialized nurse for 
KNOW-CKD in accordance with the study protocol.
A total 10  mL of whole blood was collected using a 
serum separation tube (SST) and centrifuged within 1 h 
after collection for the separation of serum prior to deliv-
ery to the central laboratory (Lab Genomics, Korea) for 
measuring creatinine. Laboratory data included complete 
blood cell counts, glucose, uric acid, blood urea nitrogen, 
serum creatinine, calcium and phosphate, lipid profiles, 
serum albumin, and high sensitivity C-reactive protein 
(hs-CRP) level at the central laboratory. Serum creatinine 
was measured by an IDMS-traceable method. Calcium 
levels were corrected by using the serum albumin level. 
Another 15  mL of the first-voided urine was also col-
lected to analyze urinary levels of albumin and creatinine 
at the central laboratory. Albuminuria was determined by 
urinary albumin-to-creatinine ratio (UACR) from spot 
urine samples, and eGFR was calculated using the four-
variable modification of diet in renal disease (MDRD) 
equation including age, sex, race, and serum creatinine 
level [14]. Plasma adiponectin (Adipogen AG, Liestal, 
Switzerland) was measured using enzyme-linked immu-
nosorbent assays. The Adiponectin (human) ELISA Kit, 
which was used in analysis of KNOW-CKD cohort sub-
jects, is a total adiponectin kit that detects the total level 
of low-, middle-, and high-molecular-weight adiponec-
tin. Other methods were described in our previous study 
[12].
Diagnosis of metabolic syndrome
The harmonizing definition [1] bases the diagnosis of 
metabolic syndrome on the presence of three or more 
of the following: (1) waist circumference (abdominal 
obesity)  >89  cm in men or  >80  cm in women, (2) tri-
glyceride  ≥150  mg/dL or taking medication for dys-
lipidemia, (3) HDL-C  <40  mg/dL in men or  <50  mg/
dL in women or taking medication, (4) systolic blood 
pressure  ≥130  mmHg and/or diastolic blood pres-
sure ≥85 mmHg or taking medication for hypertension, 
(5) fasting glucose ≥100 mg/dL or taking medication for 
diabetes. Defining thresholds for abdominal obesity are 
based on the Asian population [15].
Statistical analyses
Continuous variables were represented by using 
mean ±  standard deviation or the median (interquartile 
range), while categorical variables were represented as 
the number of subjects (percentage). Normality of distri-
bution was ascertained by the Kolmogorov–Smirnov test. 
To compare differences between patients with and with-
out metabolic syndrome, Student’s t test or the Mann–
Whitney U-test was used for continuous variables and 
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the Chi-square test for categorical variables. Univariate 
and multiple linear regression analyses were performed 
to determine independent factors associated with adi-
ponectin level. Regarding the distribution of variables, 
adiponectin level, triglyceride, hs-CRP, and UACR were 
transformed to natural logarithm values for linear regres-
sion analysis. The independent predictive role of adi-
ponectin level for the presence of metabolic syndrome 
was confirmed by multiple logistic regression analysis, 
which included significant variables in the comparison 
of baseline characteristics according to the presence of 
metabolic syndrome and multiple linear regression anal-
ysis. For further investigation beyond multiple logistic 
regression analysis, a cubic spline model was developed 
to illustrate systemic relations between adiponectin level 
and the risk of metabolic syndrome. We also conducted 
baseline subgroup analyses stratified by cause of chronic 
kidney disease, sex, age, diabetes mellitus, body mass 
index, UACR, eGFR, statin use, and angiotensin II recep-
tor blocker (ARB). The trend for the mean adiponectin 
level across the numbers of metabolic syndrome com-
ponents was verified by the trend test. Statistical analy-
sis was performed with IBM SPSS Statistics for Windows 
version 23.0 (IBM SPSS Inc., Chicago, IL, USA). P values 
less than 0.05 were considered significant.
Results
Baseline characteristics according to the presence 
of metabolic syndrome
The baseline characteristics are shown in Table  1. The 
mean age of the study population was 53.5 ± 12.4 years 
and 803 (60.7%) patients were men. There were 153 
(11.6%), 243 (18.4%), 511 (38.7%), 312 (23.6%), and 
103 (7.8%) patients included in stage 1–5 chronic kid-
ney disease groups, respectively. The mean eGFR value 
was 49.3 ±  29.8  mL/min/1.73  m2, and the median adi-
ponectin level was 10.7 (6.2–17.8)  μg/mL. Metabolic 
syndrome was present in 585 (44.3%) patients. Patients 
were divided into 2 groups according to the presence of 
metabolic syndrome. UACR [208 (45–533) vs. 398 (113–
1557)  mg/g Cr] and hs-CRP [0.05 (0.02–0.18) vs. 0.12 
(0.04–0.34) mg/dL] were higher, while eGFR (53.7 ± 30.9 
vs. 43.8 ±  27.3  mL/min/1.73  m2) and adiponectin level 
[12.5 (7.1–19.6) vs. 8.6 (5.3–14.9)  μg/mL] were signifi-
cantly lower in the metabolic syndrome group compared 
to the non-metabolic syndrome group.
Crude prevalence rates of metabolic syndrome, based 
on the combination of chronic kidney disease stages 
and quartilized adiponectin levels, are shown in Fig.  1. 
Cross-categorization was performed based on the com-
bination of chronic kidney disease stages and quarti-
lized adiponectin categories. Crude prevalence rates of 
metabolic syndrome were higher according to increased 
adiponectin levels in chronic kidney disease stage 1 [Q1 
vs. Q4, 21 (45.7%) vs. 2 (4.3%)], 2 [47 (51.1%) vs. 6 (6.5%)], 
and stage 3 [80 (35.4%) vs. 32 (14.2%)] groups, but these 
correlations were blunted in stage 4 group. Furthermore, 
in stage 5 group, highest-level adiponectin group had the 
most number of subjects diagnosed with metabolic syn-
drome [5 (8.6%) vs. 24 (41.4%)].
Relationship between clinical and biochemical variables 
and adiponectin level
Univariate linear regression analysis was performed to 
determine the relationship between clinical and bio-
chemical variables and the adiponectin level (Table  2). 
In the analysis, age (β =  0.005), phosphate (β =  0.284), 
total cholesterol (per 10 mg/dL, β = 0.015), HDL-C (per 
10 mg/dL, β = 0.116), UACR (per 1 log, β = 0.088), and 
diuretics (β = 0.141) were significantly positively related 
to adiponectin level, while sex (male, β = −0.366), smok-
ing (β = −0.224), body mass index (β = −0.053), waist 
circumference (β = −0.020), hemoglobin (β = −0.159), 
serum albumin (β  =  −0.572), glucose (per 10  mg/dL, 
β  =  −0.012), calcium (β  =  −0.127), triglyceride (per 
1  log, β  =  −0.332), hs-CRP (per 1 log, β  =  −0.050), 
eGFR (per 10 mL/min/1.73 m2, β = −0.066), and fibrate 
(β  =  −0.509) were negatively related with statistical 
significance.
To further clarify the independent association of 
adiponectin level with clinical and biochemical vari-
ables, multiple linear regression analysis was performed 
with the variables that had significant differences in 
the comparison of baseline characteristics accord-
ing to the presence of metabolic syndrome and uni-
variate linear regression analysis. In the analysis, waist 
circumference (β = −0.020), hemoglobin (β = −0.069), 
serum albumin (β  =  −0.326), triglyceride (per 1  log, 
β = −0.192), HDL-C (per 10 mg/dL, β = 0.097), hs-CRP 
(per 1 log, β = −0.053), eGFR (per 10 mL/min/1.73 m2, 
β = −0.056), and fibrate use (β = −0.358) were indepen-
dently related to adiponectin level.
Adiponectin level is independently associated with the 
presence of metabolic syndrome
The relationship between the presence of metabolic 
syndrome and adiponectin level was evaluated by mul-
tiple logistic regression analysis with adjustments for 
age, sex, smoking status, body mass index, hemoglobin, 
serum albumin, uric acid, phosphate, hs-CRP, UACR, 
and eGFR. In addition, the past history of coronary 
artery disease and cerebrovascular disease, and current 
medication with ARB, diuretics, statins, ezetimibe, and 
fibrates were also adjusted (Table 3). In the fully adjusted 
model, decreased adiponectin levels were still indepen-
dently associated with the risk of metabolic syndrome 
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Table 1 Baseline characteristics of subjects
Variables Total
n = 1322
Without MS
n = 737 (55.7%)
With MS
n = 585 (44.3%)
P
Age (years) 53.5 ± 12.4 51.5 ± 12.7 56.1 ± 11.5 <0.001
Sex, men (%) 803 (60.7) 430 (58.3) 373 (63.8) 0.045
Smoking (%) 645 (48.8) 335 (45.5) 310 (53.0) 0.006
BMI (kg/m2) 24.4 ± 3.4 23.0 ± 2.9 26.1 ± 3.2 <0.001
Waist (cm) 87.1 ± 9.7 82.8 ± 8.6 92.6 ± 8.3 <0.001
SBP (mmHg) 128.0 ± 16.3 123.1 ± 14.1 134.1 ± 17.0 <0.001
DBP (mmHg) 76.8 ± 11.3 75.2 ± 10.7 78.8 ± 11.6 <0.001
CKD stage (%) <0.001
 Stage 1 153 (11.6) 107 (14.5) 46 (7.9)
 Stage 2 243 (18.4) 151 (20.5) 92 (15.7)
 Stage 3 511 (38.7) 285 (38.7) 226 (38.6)
 Stage 4 312 (23.6) 149 (20.2) 163 (27.9)
 Stage 5 103 (7.8) 45 (6.1) 58 (9.9)
Cause of CKD (%) <0.001
 Glomerulonephritis 420 (31.8) 278 (37.7) 142 (24.3)
 Diabetes mellitus 295 (22.3) 87 (11.8) 208 (35.6)
 Hypertension 273 (20.7) 132 (17.9) 141 (24.1)
 PKD 239 (18.1) 181 (24.6) 58 (9.9)
Laboratory findings
 Hemoglobin (g/dL) 12.8 ± 2.0 12.9 ± 1.9 12.7 ± 2.1 0.303
 Albumin (g/dL) 4.19 ± 0.40 4.22 ± 0.37 4.15 ± 0.43 0.002
 Glucose (mg/dL) 107.6 ± 36.0 98.7 ± 23.2 118.7 ± 45.0 <0.001
 Uric acid (mg/dL) 7.12 ± 1.99 6.85 ± 1.94 7.47 ± 1.99 <0.001
 Calcium (mg/dL) 8.96 ± 0.45 8.95 ± 0.43 8.96 ± 0.47 0.766
 Phosphate (mg/dL) 3.70 ± 0.66 3.65 ± 0.61 3.78 ± 0.71 <0.001
 Cholesterol (mg/dL) 173.8 ± 37.5 172.6 ± 35.4 175.4 ± 39.9 0.191
 TG (mg/dL) 154.3 ± 96.2 113.8 ± 57.8 205.3 ± 109.7 <0.001
 HDL‑C (mg/dL) 49.6 ± 15.8 55.2 ± 15.4 42.7 ± 13.5 <0.001
 LDL‑C (mg/dL) 96.6 ± 30.7 96.5 ± 29.4 96.8 ± 32.2 0.889
 hs‑CRP (mg/dL) 0.07 (0.02–0.25) 0.05 (0.02–0.18) 0.12 (0.04–0.34) <0.001
 UACR (mg/g Cr) 273 (65–793) 208 (45–533) 398 (113–1557) <0.001
 eGFR (mL/min/1.73 m2) 49.3 ± 29.8 53.7 ± 30.9 43.8 ± 27.3 <0.001
 Adiponectin (μg/mL) 10.7 (6.2–17.8) 12.5 (7.1–19.6) 8.6 (5.3–14.9) <0.001
  Male 9.1 (5.2–15.4) 10.5 (5.9–17.1) 7.7 (4.7–13.4) <0.001
  Female 13.1 (8.1–21.1) 14.4 (9.6–22.5) 10.8 (7.0–17.9) <0.001
  DM 10.5 (5.8–19.1) 13.4 (7.6–23.2) 8.0 (5.2–12.4) 0.001
  Non‑DM 10.8 (6.3–17.5) 12.4 (7.0–19.0) 9.7 (5.4–17.3) <0.001
Co‑morbidity, n (%)
 Hypertension 1215 (91.9) 651 (92.1) 564 (97.2) <0.001
 DM 425 (32.1) 125 (17.0) 300 (51.3) <0.001
 CVD 114 (8.6) 53 (7.2) 61 (10.4) 0.037
 CAD 99 (7.5) 35 (4.7) 64 (10.9) <0.001
 PAD 24 (1.8) 9 (1.2) 15 (2.6) 0.069
 CHF 11 (0.8) 4 (0.5) 7 (1.2) 0.194
 Arrhythmia 29 (2.2) 16 (2.2) 13 (2.2) 0.950
Medication, n (%)
 ACEi 166 (12.6) 93 (12.6) 73 (12.5) 0.939
 ARB 1046 (79.1) 562 (76.3) 484 (82.7) 0.004
 Diuretics 432 (32.7) 171 (23.2) 261 (44.6) <0.001
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in chronic kidney disease patients [adiponectin, 1  μg/
mL increase, odds ratio (OR), 95% confidence interval 
(CI) = 0.956 (0.937–0.976), P < 0.001]. Furthermore, the 
independent association was still significant in diabetic 
[OR (95% CI) = 0.942 (0.911–0.974), P < 0.001] or non-
diabetic [OR (95% CI) = 0.967 (0.939–0.997), P = 0.031] 
nephropathy after adjustment for multiple confounding 
variables. For a more specific explanation of non-diabetic 
groups, hypertensive and glomerulonephritis groups still 
showed independent association between high adiponec-
tin levels and presence of metabolic syndrome, while 
polycystic kidney disease group did not show any signifi-
cance in the full adjustment model (Table 4).
The results of the cubic splines graph illustrating 
the association between adiponectin levels and the 
risk of metabolic syndrome is shown in Fig.  2. A trend 
towards decreased association of metabolic syndrome 
was observed in chronic kidney disease patients with 
higher adiponectin levels. In addition, when the subjects 
were divided into 6 groups according to the number of 
metabolic syndrome components, the adiponectin level 
decreased as the number of components increased (P for 
the trend <0.001, Fig. 3). 
Discussion
In the general population, adiponectin may decrease the 
risk for metabolic disturbance-related diseases such as 
obesity, type 2 diabetes, and metabolic syndrome [16]. 
However, there has been an apparent paradox regard-
ing its diverse correlations contributing to unfavorable 
clinical implications, including cardiac dysfunction, pul-
monary disease, and chronic kidney disease. Although 
several existing theories suggest such paradox, the exact 
mechanism of hyperadiponectinemia in these disease 
entities remains incomprehensible. In particular, high 
serum adiponectin levels predict mortality and progres-
sion to end-stage renal disease in patients with kidney 
disease [17]. Given the opposite results between hyper- 
and hypoadiponectinemia on renal progression, car-
diovascular outcomes, or metabolic disturbance-related 
disease, we have clarified the scope between circulating 
adiponectin levels and metabolic syndrome using a well-
established chronic kidney disease cohort database. As a 
result, we clearly showed that hypoadiponectinemia was 
independently associated with the presence of metabolic 
syndrome, even after adjusting for multiple confounding 
factors including traditional risk factors, co-morbidities, 
and medication use.
In the present study, adiponectin level was negatively 
associated with eGFR, which is fairly consistent with 
previous investigations. Since the major clearance pro-
cess of adiponectin occurs in the liver, explaining the 
exact mechanism of high adiponectin levels in low eGFR 
patients is not simple, and the causal relationship is 
unclear. In patients with chronic kidney disease, chronic 
inflammation, oxidative stress, and sympathetic overac-
tivity are common clinical features, and these features 
might inhibit adiponectin expression [18]. However, the 
kidney has been regarded as a key organ for biodegrada-
tion of various proteins and cytokines; thus, decreased 
MS metabolic syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CKD chronic kidney disease, PKD, polycystic kidney disease, 
TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hs-CRP high sensitivity C-reactive protein, UACR urine albumin-
to-creatinine ratio, eGFR estimated glomerular filtration rate, DM diabetes mellitus, CVD cerebrovascular disease, CAD coronary artery disease, PAD peripheral artery 
disease, CHF congestive heart failure, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
Table 1 continued
Variables Total
n = 1322
Without MS
n = 737 (55.7%)
With MS
n = 585 (44.3%)
P
 Beta blocker 368 (27.8) 142 (19.3) 226 (38.6) <0.001
 Statin 649 (49.1) 321 (43.6) 328 (56.1) <0.001
 Ezetimibe 95 (7.2) 42 (5.7) 53 (9.1) 0.019
 Fibrate 31 (2.3) 7 (0.9) 24 (4.1) <0.001
Fig. 1 Crude prevalence rates of MS in the 20 groups, based on the 
combination of CKD stages and quartilized APN levels. Cross‑catego‑
rization was performed based on the combination of CKD stages and 
quartilized APN category. Crude prevalence rates of MS were higher 
according to increased APN levels in CKD stage 1 [Q1 vs. Q4, 21 
(45.7%) vs. 2 (4.3%)], stage 2 [47 (51.1%) vs. 6 (6.5%)], and stage 3 [80 
(35.4%) vs. 32 (14.2%)] groups, but these correlations were blunted in 
stage 4. Furthermore, in stage 5 patients, group with the highest APN 
level had the most number of subjects diagnosed with metabolic 
syndrome [5 (8.6%) vs. 24 (41.4%)]. MS metabolic syndrome, CKD 
chronic kidney disease, APN adiponectin
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kidney function could promote the accumulation of 
adiponectin in the systemic blood. Although a counter-
regulatory hyperadiponectinemia in acute pathologic 
conditions such as full-blown nephrotic syndrome has 
been reported [19], the evidence showing decreased 
adiponectin levels after kidney transplantation regard-
less of serum creatinine level or insulin resistance also 
strengthens the former postulation [20]. In addition, 
the ‘chronic’ damaged kidney function and consequent 
uremic milieu also results in hyperadiponectinemia 
through the inhibition of adiponectin gene expression 
and the activation of the renin-angiotensin system [21]. 
Meanwhile, relatively lower adiponectin levels com-
pared to previous studies that investigated the impact of 
Table 2 Linear regression analysis for the association of adiponectin with clinical and biochemical variables
a Log transformed, adiponectin was also transformed by log
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hs-CRP high sensitivity C-reactive protein, UACR urinary albumin-to-creatinine 
ratio, eGFR estimated glomerular filtration rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
Variables Univariate Multiple
β (95% CI) P β (95% CI) P
Age (per 1 year) 0.005 (0.002 to 0.008) 0.004 0.002 (−0.002 to 0.005) 0.346
Sex (male) −0.366 (−0.450 to −0.283) <0.001 −0.067 (−0.196 to 0.061) 0.305
Smoking −0.224 (−0.307 to −0.141) <0.001 0.002 (−0.111 to 0.115) 0.975
Body mass index (per 1 kg/m2) −0.053 (−0.065 to −0.041) <0.001
Waist circumference (per 1 cm) −0.020 (−0.024 to −0.016) <0.001 −0.008 (−0.013 to −0.003) 0.002
Systolic blood pressure (per 10 mmHg) 0.007 (−0.019 to 0.033) 0.584
Diastolic blood pressure (per 10 mmHg) −0.005 (−0.042 to 0.033) 0.811
Laboratory findings
 Hemoglobin (per 1 g/dL) −0.159 (−0.178 to −0.139) <0.001 −0.069 (−0.099 to −0.039) <0.001
 Albumin (per 1 g/dL) −0.572 (−0.672 to −0.473) <0.001 −0.326 (−0.451 to −0.202) <0.001
 Glucose (per 10 mg/dL) −0.012 (−0.024 to −0.001) 0.041 −0.009 (−0.021 to 0.003) 0.130
 Uric acid (per 1 mg/dL) 0.014 (−0.007 to 0.036) 0.179
 Calcium (per 1 mg/dL) −0.127 (−0.220 to −0.034) 0.008
 Phosphate (per 1 mg/dL) 0.284 (0.222 to 0.345) <0.001
 Cholesterol (per 10 mg/dL) 0.015 (0.004 to 0.026) 0.008
 Triglyceride (per 1 log)a −0.332 (−0.408 to −0.256) <0.001 −0.192 (−0.283 to −0.101) <0.001
 HDL‑C (per 10 mg/dL) 0.116 (0.090 to 0.142) <0.001 0.097 (0.066 to 0.128) <0.001
 LDL‑C (per 10 mg/dL) 0.009 (−0.005 to 0.023) 0.201
 hs‑CRP (per 1 log)a −0.050 (−0.076 to −0.024) <0.001 −0.053 (−0.080 to −0.026) <0.001
 UACR (per 1 log)a 0.088 (0.062 to 0.113) <0.001 0.028 (−0.001 to 0.056) 0.055
 eGFR (per 10 mL/min/1.73 m2) −0.066 (−0.080 to −0.052) <0.001 −0.059 (−0.078 to −0.041) <0.001
Co‑morbidities
 Diabetes mellitus 0.018 (−0.072 to 0.108) 0.693
 Hypertension −0.021 (−0.175 to 0.132) 0.786
 Coronary artery disease 0.071 (−0.088 to 0.230) 0.379
 Peripheral artery disease 0.116 (−0.198 to 0.429) 0.470
 Cerebrovascular disease 0.010 (−0.139 to 0.159) 0.897
 Congestive heart failure −0.363 (−0.823 to 0.098) 0.122
 Arrhythmia −0.156 (−0.441 to 0.130) 0.285
Medications
 ACEi 0.045 (−0.082 to 0.171) 0.490
 ARB −0.089 (−0.203 to 0.024) 0.123
 Diuretics 0.141 (0.051 to 0.231) 0.002 0.042 (−0.052 to 0.137) 0.377
 Beta blocker −0.059 (−0.153 to 0.035) 0.221
 Statin −0.051 (−0.135 to 0.033) 0.236
 Ezetimibe −0.081 (−0.243 to 0.081) 0.328
 Fibrate −0.509 (−0.785 to −0.233) <0.001 −0.358 (−0.627 to −0.089) 0.009
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adiponectin levels in patients with chronic kidney disease 
might be due to the difference of mean eGFR in the pre-
sent study population [22].
Our study showed that UACR was positively associated 
with adiponectin level. Even though the adipocyte is the 
chief secretory organ of adiponectin, the kidney is a major 
target organ through the adiponectin receptors (Adipo R) 
1 and 2 in the intra-renal arterioles, endothelium, podo-
cytes, mesangial cells of the glomerulus, and proximal 
tubular cells [23]. In experimental studies, adiponectin 
knockout mice showed exacerbation of albuminuria and 
renal fibrosis, and the restoration of adiponectin showed 
normalization of albuminuria, improvement of podocyte 
foot process effacement, and reduced urinary and glo-
merular markers of oxidant stress in adiponectin knock-
out mice [24]. In addition, the renal expression of Adipo 
R1 and R2 in adenine-induced chronic kidney disease 
rats is significantly increased compared to controls, and 
positively related to the adiponectin level in serum or 
urine [25]. All things taken together including previous 
mentioned evidence, the adiponectin level is substantially 
increased in full-blown nephrotic syndrome compared to 
controls [19], and it can be postulated that adiponectin 
is increased for counter-regulatory or kidney-protective 
purposes in damaged kidneys, similar to albuminuria.
From the clinical aspect, a landmark study showed that 
high adiponectin levels are associated with a lower risk 
of myocardial infarction in men [26], and this was fol-
lowed by several remarkable studies that showed that 
higher adiponectin levels are associated with favorable 
clinical outcomes [27]. The favorable adiponectin effect is 
independently associated with not only eGFR and albu-
minuria, but also all-cause mortality and cardiovascu-
lar events in chronic kidney disease [11]. However, with 
established chronic kidney disease, the inverse relation-
ship is not generally implicated and the findings are more 
complicated. The paradoxical increase of adiponectin 
level in those with the highest mortality may have been 
secondary to weight loss, which is a known stimulator 
of adiponectin as well as an independent risk factor in 
end-stage renal or heart disease patients [28]. The expres-
sion of adiponectin receptor mRNA on peripheral blood 
mononuclear cells in end-stage renal disease patients on 
hemodialysis [29] is increased and significantly related to 
subcutaneous and visceral fat. These findings imply that 
the inverse relationship between adiponectin level and 
renal function could result from the resistance effect of 
adiponectin in patients with chronic uremia, thus the 
Table 3 Adiponectin as  a risk factor of  metabolic syn-
drome
Adiponectin 1 μg/mL increase, subgroup analysis was performed according to 
the cause of chronic kidney disease
Model 1: adjusted for age, sex, smoking status, and body mass index
Model 2: adjusted for model 1 + hemoglobin, serum albumin, uric acid, and 
phosphate
Model 3: adjusted for model 2 + hs-CRP, urinary albumin-to-creatinine ratio, and 
eGFR
Model 4: adjusted for model 3 + coronary artery disease, cerebrovascular 
disease, ARB, diuretics, statin, ezetimibe, and fibrate
DM diabetes mellitus, hs-CRP high sensitivity C-reactive protein, eGFR estimated 
glomerular filtration rate, ARB angiotensin II receptor blocker
Odds ratio (95% confidence interval)
Total P
Crude 0.966 (0.954–0.978) <0.001
Model 1 0.983 (0.969–0.997) 0.015
Model 2 0.961 (0.946–0.977) <0.001
Model 3 0.959 (0.940–0.979) <0.001
Model 4 0.956 (0.937–0.976) <0.001
Table 4 Subgroup analyses of relationship between adiponectin levels and presence of metabolic syndrome
Adiponectin 1 μg/mL increase, subgroup analysis was performed according to the cause of chronic kidney disease
Model 1: adjusted for age, gender, smoking status, and body mass index
Model 2: adjusted for model 1 + hemoglobin, serum albumin, uric acid, phosphate, and parathyroid hormone
Model 3: adjusted for model 2 + hs-CRP, urine albumin-to-creatinine ratio, and eGFR
Model 4: adjusted for model 3 + coronary artery disease, cerebrovascular disease, ARB, diuretics, statin, ezetimibe, and fibrate
DM diabetic mellitus, HTN hypertension, GN glomerulonephritis, PKD polycystic kidney disease, hs-CRP high sensitivity C-reactive protein, eGFR estimated glomerular 
filtration rate, ARB angiotensin II receptor blocker
Odds ratio (95% confidence interval)
DM Non-DM
Total HTN GN PKD
Crude 0.964 (0.943–0.984) 0.951 (0.935–0.967) 0.941 (0.912–0.971) 0.955 (0.931–0.979) 0.944 (0.904–0.987)
Model 1 0.973 (0.949–0.997) 0.969 (0.951–0.988) 0.949 (0.916–0.984) 0.980 (0.952–1.009) 0.954 (0.907–1.004)
Model 2 0.952 (0.923–0.981) 0.957 (0.935–0.980) 0.944 (0.905–0.985) 0.949 (0.913–0.987) 0.962 (0.911–1.016)
Model 3 0.946 (0.913–0.980) 0.957 (0.932–0.983) 0.950 (0.901–1.003) 0.942 (0.900–0.986) 0.950 (0.899–1.004)
Model 4 0.933 (0.898–0.970) 0.959 (0.932–0.986) 0.939 (0.885–0.996) 0.942 (0.896–0.990) 0.969 (0.913–1.028)
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regulation of expression, secretion, or excretion of adi-
ponectin is destroyed [30].
Nevertheless, the present analysis indicates that 
adiponectin level was independently associated with 
the risk of metabolic syndrome in chronic kidney dis-
ease patients after adjustment for confounding factors 
including eGFR and UACR. Adiponectin is secreted 
from visceral fat. Therefore, a strong relationship 
between adiponectin level and metabolic components 
including triglycerides, HDL-C, and waist measure-
ments might overwhelm the association with renal 
function. In particular, waist enlargement is the sec-
ond-most common metabolic syndrome component, 
followed by glucose. In this analysis, the relationship 
between adiponectin level and the risk of metabolic 
syndrome would mostly be influenced by the preva-
lence of larger-waist subjects. In obese subjects, adi-
ponectin levels were lower despite the fact that adipose 
tissue is its source [31]. In addition, adiponectin level 
was demonstrated to be lower in body weight reduc-
tion subjects [32]. Waist circumference is not only a 
simple indicator of obesity but is also related to non-
traditional risk factors such as inflammation [33]. The 
strong relationship between metabolic derangements 
such as waist circumference or hypertriglyceridemia 
and adiponectin level suggests that these metabolic 
factors are overwhelming the association between adi-
ponectin level and low eGFR or albuminuria in patients 
with chronic kidney disease.
In the end, we found several results. First, serum albu-
min levels were significantly and independently associ-
ated with adiponectin levels in our analysis. In fact, this 
clear finding has already been reported in several previ-
ous investigations [11, 34], and the mechanistic linkage 
have postulated through protein-energy wasting syn-
drome (PEWS), which is the chief contributor to adverse 
clinical outcomes in uremic patients [17]. Given that 
serum albumin levels have been regarded as major mark-
ers of either malnutrition or PEWS, the inverse relation-
ship between serum albumin and circulating adiponectin 
concentrations might be in line with our findings. Sec-
ond, low hemoglobin levels were independently associ-
ated with high adiponectin levels, and these findings have 
also been reported in several previous investigations [35, 
36]. It remains uncertain why low hemoglobin concen-
trations are independently associated with high circulat-
ing adiponectin levels. One plausible explanation is the 
increased expression of hypoxia inducible factor (HIF), 
which results from anemia-induced tissue hypoxia. A 
recent experimental study clearly indicated that HIF-1 
activation with a variety of stimuli significantly increases 
adiponectin expression [37]. Another suggestion is that 
circulating adiponectin would be chiefly secreted from 
bone marrow fat, with an inverse correlation between fat 
mass and circulating adiponectin levels [38]. Considering 
that marrow adipocyte is a negative regulator of hemat-
opoiesis [39], we would assume an independent relation-
ship between circulating adiponectin and hemoglobin 
levels.
Several limitations of our study must be acknowl-
edged. First, the study was performed with an analysis of 
Fig. 2 Cubic spline regression models of the estimated probability 
(with 95% confidence interval) of metabolic syndrome according to 
the adiponectin level. Multiple model adjusted for age, sex, smoking 
status, body mass index, hemoglobin, serum albumin, uric acid, 
phosphate, high sensitivity C‑reactive protein, urinary albumin‑to‑
creatinine ratio, estimated glomerular filtration rate, coronary artery 
disease, cerebrovascular disease, angiotensin II receptor blocker, 
diuretics, statin, ezetimibe, and fibrate
Fig. 3 The mean value of adiponectin level according to the number 
of metabolic syndrome components. Each bar represents the mean 
and 95% confidence interval of adiponectin level. Adiponectin level 
are increased in parallel with the number of metabolic syndrome 
components (P for trend <0.001). MS metabolic syndrome
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cross-sectional data, the causative role of adiponectin on 
development of metabolic syndrome is still inconclusive. 
Thus, given the differences in overall outcome between 
previous studies, further research with a prospective 
design in this area should be prioritized. Second, in the 
course of defining metabolic syndrome, the waist cir-
cumference was evaluated using Asian criteria. Although 
there is controversy about defining the waist criteria in 
metabolic syndrome diagnosis, the Korean Diabetes 
Association presented Korean waist criteria, which is the 
same as the Asian criteria in the harmonizing definition. 
Third, the genetic polymorphism of adiponectin levels 
was also reported [40], thus the fact that a single ethnic-
ity Korean cohort was used should be considered during 
interpretation.
Conclusion
In conclusion, low adiponectin levels were independently 
associated with the presence of metabolic syndrome in 
chronic kidney disease patients. The relationship showed 
linearity throughout the categorical adiponectin levels. A 
strategy to modulate serum adiponectin might be help-
ful to improve metabolic derangements in patients with 
chronic kidney disease.
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